Portal de Periódicos da CAPES

1NM-PP1 Treatment of Mice Infected with Toxoplasma gondii

2011; Japanese Society of Veterinary Science; Volume: 73; Issue: 10 Linguagem: Inglês

10.1292/jvms.11-0085

1347-7439

Tatsuki Sugi, Kentaro Kato, Kyousuke Kobayashi, Hitomi Kurokawa, Hitoshi Takemae, Haiyan Gong, Frances C. Recuenco, Tatsuya Iwanaga, Taisuke Horimoto, Hiroomi Akashi,

Herpesvirus Infections and Treatments

Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9: 667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NM-PP1 with oral administration didn't change the survival rates of infected mice.